Ginkgo Bioworks (DNA) Competitors $7.41 -0.58 (-7.21%) Closing price 03:59 PM EasternExtended Trading$7.58 +0.17 (+2.24%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. ARWR, CGON, GMTX, TVTX, RXRX, TARS, BEAM, APGE, SDGR, and CNTAShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Arrowhead Pharmaceuticals (ARWR), CG Oncology (CGON), Gemini Therapeutics (GMTX), Travere Therapeutics (TVTX), Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Apogee Therapeutics (APGE), Schrödinger (SDGR), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Arrowhead Pharmaceuticals CG Oncology Gemini Therapeutics Travere Therapeutics Recursion Pharmaceuticals Tarsus Pharmaceuticals Beam Therapeutics Apogee Therapeutics Schrödinger Centessa Pharmaceuticals Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings. Is ARWR or DNA more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Ginkgo Bioworks' return on equity of -58.54% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -236.60% -64.09% Ginkgo Bioworks -298.78%-58.54%-34.24% Does the MarketBeat Community prefer ARWR or DNA? Arrowhead Pharmaceuticals received 527 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 65.44% of users gave Arrowhead Pharmaceuticals an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformArrowhead PharmaceuticalsOutperform Votes55165.44% Underperform Votes29134.56% Ginkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Which has more risk and volatility, ARWR or DNA? Arrowhead Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Does the media prefer ARWR or DNA? In the previous week, Arrowhead Pharmaceuticals had 29 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 35 mentions for Arrowhead Pharmaceuticals and 6 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 1.31 beat Arrowhead Pharmaceuticals' score of 0.83 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 6 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ARWR or DNA? Arrowhead Pharmaceuticals presently has a consensus price target of $42.13, suggesting a potential upside of 173.93%. Ginkgo Bioworks has a consensus price target of $5.77, suggesting a potential downside of 22.54%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67Ginkgo Bioworks 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Which has higher earnings and valuation, ARWR or DNA? Arrowhead Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$545.21M3.90-$599.49M-$1.40-10.98Ginkgo Bioworks$237.42M1.84-$892.87M-$9.16-0.81 Do insiders and institutionals hold more shares of ARWR or DNA? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryArrowhead Pharmaceuticals beats Ginkgo Bioworks on 11 of the 18 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$435.71M$2.92B$5.36B$19.40BDividend YieldN/A1.72%5.22%3.84%P/E Ratio-0.5730.7126.6234.34Price / Sales1.84398.27391.3034.82Price / CashN/A168.6838.2517.51Price / Book0.343.286.804.70Net Income-$892.87M-$72.17M$3.23B$1.02B7 Day Performance-4.43%4.13%4.02%-1.17%1 Month Performance1.29%7.50%12.19%9.98%1 Year PerformanceN/A-28.22%17.04%3.41% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks1.1138 of 5 stars$7.41-7.2%$5.77-22.2%N/A$433.96M$237.42M-0.57640Positive NewsARWRArrowhead Pharmaceuticals3.5209 of 5 stars$13.97+7.2%$41.44+196.7%-34.4%$1.92B$2.50M-2.70400News CoveragePositive NewsAnalyst ForecastGap UpCGONCG Oncology2.2251 of 5 stars$25.16+6.0%$57.70+129.3%-10.7%$1.92B$1.14M-17.7261Analyst ForecastGMTXGemini TherapeuticsN/A$44.24-0.1%N/A+54.4%$1.92BN/A-44.2430TVTXTravere Therapeutics3.0036 of 5 stars$21.54+7.6%$31.79+47.6%+184.6%$1.91B$273.53M-5.25460Positive NewsRXRXRecursion Pharmaceuticals2.4148 of 5 stars$4.64+7.2%$7.60+63.8%-53.5%$1.87B$59.82M-3.03400Positive NewsGap DownTARSTarsus Pharmaceuticals3.2652 of 5 stars$44.20-1.3%$66.33+50.1%+15.9%$1.86B$233.67M-11.6050Positive NewsBEAMBeam Therapeutics3.1269 of 5 stars$18.24+4.8%$48.75+167.3%-28.5%$1.83B$63.58M-10.36510Positive NewsAPGEApogee Therapeutics2.1513 of 5 stars$39.58+6.1%$94.60+139.0%-23.0%$1.78BN/A-16.3691Positive NewsGap DownSDGRSchrödinger2.948 of 5 stars$24.17+1.1%$32.80+35.7%-4.7%$1.77B$207.54M-10.33790News CoveragePositive NewsCNTACentessa Pharmaceuticals3.5474 of 5 stars$13.15+6.9%$27.00+105.3%+51.4%$1.75B$6.85M-8.59200Positive NewsInsider TradeAnalyst RevisionGap Up Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Competitors CG Oncology Competitors Gemini Therapeutics Competitors Travere Therapeutics Competitors Recursion Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Beam Therapeutics Competitors Apogee Therapeutics Competitors Schrödinger Competitors Centessa Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
